Lana Kwong

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Alexander G.G. Turpie, W. D. Fisher, Kenneth A. Bauer et al. · Journal of Thrombosis and Haemostasis · 2005 · 301 citations · Full text

Total Knee Replacement, Thrombosis, Venous Disease +9

Cementless total knee replacement fixation

Lana Kwong, Evan S. Nielsen, D. R. Ruiz et al. · The Bone & Joint Journal · 2014 · 43 citations

Hip Arthroplasty, Biomechanics, Bone Repair +13

Shielding of the patientʼs gonads during intramedullary interlocking femoral nailing.

Lana Kwong, Paul H. Johanson, Daniel M. Zinar et al. · Journal of Bone and Joint Surgery · 1990 · 36 citations

Radiation Effect, Radiation Exposure, Surgery +18

Project RED Impacts Patient Experience

Ramon S. Cancino, Chris Manasseh, Lana Kwong et al. · Journal of Patient Experience · 2017 · 28 citations · Full text

COMPARISON OF RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR–AND SUBCUTANEOUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT (RECORD4: A PHASE III STUDY)

Alexander G.G. Turpie, K.A. Bauer, B. Davidson et al. · 2010 · 17 citations

Pharmacotherapy, Orthopaedic Surgery, Thrombosis +17